{
  "patent_number": "US 8399514",
  "country": "US",
  "title": "Using Dimethyl Fumarate to Treat Multiple Sclerosis",
  "original_title": "Treatment for multiple sclerosis",
  "summary": "A patent detailing the specific daily dosage of 480mg of dimethyl fumarate for treating multiple sclerosis to protect nerve cells.",
  "what_it_does": "This patent describes a specific treatment protocol for multiple sclerosis (MS) using dimethyl fumarate or monomethyl fumarate. The core mechanism involves administering a total of 480 mg per day, which the patent claims activates the Nrf2 cellular pathway. This pathway is responsible for protecting cells from oxidative stress, which helps reduce the damage to the protective coating of nerves (demyelination) and prevents nerve cell death. The patent specifies that this dose can be split into multiple equal administrations, such as two doses per day.",
  "what_it_does_not_cover": [
    "Does not cover dosages significantly different from the 480 mg per day threshold.",
    "Does not cover the use of dimethyl fumarate for diseases other than multiple sclerosis.",
    "Does not cover non-oral delivery methods, such as intravenous or intramuscular injections.",
    "Does not cover chemical formulations that include active ingredients beyond the specified fumarates and standard excipients."
  ],
  "filed": "2012-02-13",
  "granted": "2013-03-19",
  "expires": null,
  "status": "active",
  "holder": "Biogen Idec MA Inc",
  "holder_url": "https://patentbrief.org/company/biogen-idec-ma-inc",
  "inventors": [
    {
      "name": "Gilmore O'Neill",
      "url": "https://patentbrief.org/inventor/gilmore-oneill"
    },
    {
      "name": "Matvey E. LUKASHEV",
      "url": "https://patentbrief.org/inventor/matvey-e-lukashev"
    }
  ],
  "times_cited": 52,
  "tags": [
    "biotech",
    "pharmaceutical"
  ],
  "abstract": "Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.",
  "url": "https://patentbrief.org/patent/us/8399514/gilenya-fingolimod",
  "markdown_url": "https://patentbrief.org/patent/us/8399514/gilenya-fingolimod/md",
  "google_patents_url": "https://patents.google.com/patent/US8399514",
  "relatedPatents": []
}